Current Edition

business

Domain Therapeutics’ innovative business model gains validation through Prexton Therapeutics’ acquisition by Lundbeck for up to $1.1 billion

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech …

Continue Reading →